William Blair analyst Myles Minter has reiterated their bullish stance on ARCT stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Myles Minter has given his Buy rating due to a combination of factors that highlight the promising potential of Arcturus Therapeutics’ mRNA-based therapies. The interim data from the Phase II trial of ARCT-810, an mRNA therapy for ornithine transcarbamylase deficiency, showed significant improvements in key biomarkers such as glutamine reduction and ureagenesis enhancement. These results suggest a disease-modifying effect, which positions ARCT-810 favorably as it progresses towards regulatory discussions and pivotal studies.
Minter also notes the strong support from key opinion leaders for mRNA-based treatments in addressing OTC deficiency, which adds credibility to Arcturus’s approach. Furthermore, the anticipation surrounding the upcoming Phase II data for Arcturus’s inhaled CFTR mRNA therapy, ARCT-032, underscores the company’s potential to address major unmet medical needs. This combination of positive clinical data and strategic positioning in the mRNA therapeutic space underpins Minter’s optimistic outlook and Buy rating for Arcturus Therapeutics.
In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $45.00 price target.